BioAge Labs
BIOA
150 hedge funds and large institutions have $925M invested in BioAge Labs in 2026 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 61 increasing their positions, 38 reducing their positions, and 19 closing their positions.
717% more call options, than puts
Call options by funds: $23.3M | Put options by funds: $2.86M
181% more capital inflows, than outflows
Capital inflows: $156M | Capital outflows: $55.6M
61% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 38
47% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 19
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
7.62% more ownership
Funds ownership: 77.26% → 84.88% (+7.6%)
4% more funds holding
Funds holding: 144 → 150 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$30.1M |
| 2 |
BlackRock
New York
|
+$10.5M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$5.43M |
| 4 |
Integral Health Asset Management
New York
|
+$5.42M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$11.3M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.03M |
| 3 |
Millennium Management
New York
|
-$3.75M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.61M |
| 5 |
Y-Intercept (HK)
Hong Kong
|
-$3.36M |
BIOA Hedge Fund Activity: Q2 2026 in Review
150 of the 8,355 institutional investors tracked by Wall St. Rank reported a position in BioAge Labs (BIOA) for Q2 2026, worth a combined $925M — up 54% from $599M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new BIOA positions and 19 closed out — a net gain of 9 holders — while 61 added to existing stakes and 38 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $30.1M. The largest seller was Balyasny Asset Management, cutting an estimated $11.3M.
- 150 institutional investors held BioAge Labs (BIOA) as of Q2 2026, up from 144 in Q1 2026.
- Funds reported $925M of BioAge Labs stock for Q2 2026, up 54% quarter-over-quarter.
- 28 funds opened new BioAge Labs positions in Q2 2026 and 19 closed out, a net change of +9 holders.
- The largest BioAge Labs buyer in Q2 2026 was MPM BioImpact, an estimated $30.1M added.
- The largest BioAge Labs seller in Q2 2026 was Balyasny Asset Management, an estimated $11.3M sold.
Based on aggregated 13F filings for Q2 2026.